Aczone

Toxoplasmosis, prophylaxis of mild Toxoplasma gondii encephalitis, prophylaxis of moderate Toxoplasma gondii encephalitis + 14 more
Treatment
20 Active Studies for Aczone

What is Aczone

DapsoneThe Generic name of this drug
Treatment SummaryA sulfone is an antibiotic that targets a broad range of bacteria, but is mostly used against Mycobacterium leprae. It works by blocking the production of folic acid in susceptible organisms, similar to the way sulfonamides work. It can also be combined with pyrimethamine to treat malaria.
Dapsoneis the brand name
image of different drug pills on a surface
Aczone Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Dapsone
Dapsone
1979
46

Effectiveness

How Aczone Affects PatientsDapsone is a medication with anti-inflammatory, antibacterial, and antibiotic properties. It is most commonly used to treat leprosy, malaria, and Pneumocystic carinii pneumonia in AIDS patients. It is quickly and almost completely absorbed by the body when taken orally. It spreads to all parts of the body, but mostly stays in the skin, muscles, liver, and kidneys. Even after stopping treatment, small traces of dapsone may remain in these organs for up to 3 weeks.
How Aczone works in the bodyDapsone works against bacteria and protozoa by blocking their ability to make the chemical dihydrofolic acid. It also has anti-inflammatory effects, although the exact way it works is still not clear.

When to interrupt dosage

The recommended dosage of Aczone is contingent upon the indicated condition, such as moderate Pneumocystis pneumonia, Relapsing Polychondritis and prophylaxis of mild Pneumocystis pneumonia. The measure of dosage may differ as per the approach of delivery (e.g. Gel - Topical or Topical) listed in the table beneath.
Condition
Dosage
Administration
Toxoplasmosis
, 0.05 mg/mg, 100.0 mg, 25.0 mg, 5.0 %, 0.075 mg/mg, 0.06 mg/mg, 0.085 mg/mg
Gel, Topical, , Gel - Topical, Oral, Tablet, Tablet - Oral
prophylaxis of mild Toxoplasma gondii encephalitis
, 0.05 mg/mg, 100.0 mg, 25.0 mg, 5.0 %, 0.075 mg/mg, 0.06 mg/mg, 0.085 mg/mg
Gel, Topical, , Gel - Topical, Oral, Tablet, Tablet - Oral
Pneumonia, Pneumocystis
, 0.05 mg/mg, 100.0 mg, 25.0 mg, 5.0 %, 0.075 mg/mg, 0.06 mg/mg, 0.085 mg/mg
Gel, Topical, , Gel - Topical, Oral, Tablet, Tablet - Oral
Pneumonia, Pneumocystis
, 0.05 mg/mg, 100.0 mg, 25.0 mg, 5.0 %, 0.075 mg/mg, 0.06 mg/mg, 0.085 mg/mg
Gel, Topical, , Gel - Topical, Oral, Tablet, Tablet - Oral
prophylaxis of moderate Pneumocystis pneumonia
, 0.05 mg/mg, 100.0 mg, 25.0 mg, 5.0 %, 0.075 mg/mg, 0.06 mg/mg, 0.085 mg/mg
Gel, Topical, , Gel - Topical, Oral, Tablet, Tablet - Oral
Bullous dermatitis herpetiformis
, 0.05 mg/mg, 100.0 mg, 25.0 mg, 5.0 %, 0.075 mg/mg, 0.06 mg/mg, 0.085 mg/mg
Gel, Topical, , Gel - Topical, Oral, Tablet, Tablet - Oral
prophylaxis of mild Pneumocystis pneumonia
, 0.05 mg/mg, 100.0 mg, 25.0 mg, 5.0 %, 0.075 mg/mg, 0.06 mg/mg, 0.085 mg/mg
Gel, Topical, , Gel - Topical, Oral, Tablet, Tablet - Oral
Toxoplasmosis
, 0.05 mg/mg, 100.0 mg, 25.0 mg, 5.0 %, 0.075 mg/mg, 0.06 mg/mg, 0.085 mg/mg
Gel, Topical, , Gel - Topical, Oral, Tablet, Tablet - Oral
Acne Vulgaris
, 0.05 mg/mg, 100.0 mg, 25.0 mg, 5.0 %, 0.075 mg/mg, 0.06 mg/mg, 0.085 mg/mg
Gel, Topical, , Gel - Topical, Oral, Tablet, Tablet - Oral
Drug Resistance
, 0.05 mg/mg, 100.0 mg, 25.0 mg, 5.0 %, 0.075 mg/mg, 0.06 mg/mg, 0.085 mg/mg
Gel, Topical, , Gel - Topical, Oral, Tablet, Tablet - Oral
Pemphigus Vulgaris
, 0.05 mg/mg, 100.0 mg, 25.0 mg, 5.0 %, 0.075 mg/mg, 0.06 mg/mg, 0.085 mg/mg
Gel, Topical, , Gel - Topical, Oral, Tablet, Tablet - Oral
Relapsing Polychondritis
, 0.05 mg/mg, 100.0 mg, 25.0 mg, 5.0 %, 0.075 mg/mg, 0.06 mg/mg, 0.085 mg/mg
Gel, Topical, , Gel - Topical, Oral, Tablet, Tablet - Oral
Leprosy
, 0.05 mg/mg, 100.0 mg, 25.0 mg, 5.0 %, 0.075 mg/mg, 0.06 mg/mg, 0.085 mg/mg
Gel, Topical, , Gel - Topical, Oral, Tablet, Tablet - Oral
Bullous Systemic Lupus Erythematosus
, 0.05 mg/mg, 100.0 mg, 25.0 mg, 5.0 %, 0.075 mg/mg, 0.06 mg/mg, 0.085 mg/mg
Gel, Topical, , Gel - Topical, Oral, Tablet, Tablet - Oral
prophylaxis of moderate Toxoplasma gondii encephalitis
, 0.05 mg/mg, 100.0 mg, 25.0 mg, 5.0 %, 0.075 mg/mg, 0.06 mg/mg, 0.085 mg/mg
Gel, Topical, , Gel - Topical, Oral, Tablet, Tablet - Oral
Immune thrombocytopenic purpura
, 0.05 mg/mg, 100.0 mg, 25.0 mg, 5.0 %, 0.075 mg/mg, 0.06 mg/mg, 0.085 mg/mg
Gel, Topical, , Gel - Topical, Oral, Tablet, Tablet - Oral
HIV
, 0.05 mg/mg, 100.0 mg, 25.0 mg, 5.0 %, 0.075 mg/mg, 0.06 mg/mg, 0.085 mg/mg
Gel, Topical, , Gel - Topical, Oral, Tablet, Tablet - Oral

Warnings

There are 20 known major drug interactions with Aczone.
Common Aczone Drug Interactions
Drug Name
Risk Level
Description
Acenocoumarol
Major
The metabolism of Acenocoumarol can be increased when combined with Dapsone.
Acepromazine
Major
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Acepromazine.
Aceprometazine
Major
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Aceprometazine.
Acetophenazine
Major
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Acetophenazine.
Alimemazine
Major
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Alimemazine.
Aczone Toxicity & Overdose RiskTaking more than the recommended dose of this drug may cause a stuffy nose, fainting, or hallucinations. If necessary, steps should be taken to stabilize the patient's blood pressure.
image of a doctor in a lab doing drug, clinical research

Aczone Novel Uses: Which Conditions Have a Clinical Trial Featuring Aczone?

Presently, 144 active trials are assessing the potential of Aczone in providing relief from Bullous Systemic Lupus Erythematosus, mild Pneumocystis pneumonia and Immune thrombocytopenic purpura.
Condition
Clinical Trials
Trial Phases
Pemphigus Vulgaris
2 Actively Recruiting
Phase 1
Pneumonia, Pneumocystis
0 Actively Recruiting
prophylaxis of mild Pneumocystis pneumonia
0 Actively Recruiting
Bullous dermatitis herpetiformis
0 Actively Recruiting
prophylaxis of moderate Pneumocystis pneumonia
0 Actively Recruiting
HIV
155 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4, Early Phase 1
prophylaxis of moderate Toxoplasma gondii encephalitis
0 Actively Recruiting
prophylaxis of mild Toxoplasma gondii encephalitis
0 Actively Recruiting
Immune thrombocytopenic purpura
0 Actively Recruiting
Leprosy
0 Actively Recruiting
Pneumonia, Pneumocystis
0 Actively Recruiting
Bullous Systemic Lupus Erythematosus
0 Actively Recruiting
Toxoplasmosis
0 Actively Recruiting
Acne Vulgaris
3 Actively Recruiting
Phase 1, Phase 2, Early Phase 1
Toxoplasmosis
0 Actively Recruiting
Relapsing Polychondritis
1 Actively Recruiting
Phase 2
Drug Resistance
0 Actively Recruiting

Aczone Reviews: What are patients saying about Aczone?

5Patient Review
6/9/2016
Aczone for Acne
I've only used it for a few days and I can tell the condition of my skin is already improving. I've tried so many acne products, and nothing really has worked-- until now. I have hormonal painful acne and have been struggling with it for the past 2 years. So far, this product has given me great results.
5Patient Review
2/27/2022
Aczone for Acne
Aczone has quickly and effectively cleared up my breakouts, sometimes in just one to two nights. Not only that, but it also doesn't dry out or flake my skin like other treatments I've tried (looking at you, biacna). If you suffer from hormonal cystic acne or regular old breakouts as an adult, do yourself a favor and give this stuff a try.
5Patient Review
2/18/2020
Aczone for Acne
This acne cream is very effective and doesn't dry out my skin. However, it's very expensive. I've been able to find a discount through CarePoint, which is $60 a bottle about 6-8 weeks. My insurance doesn't cover this and estimates my out of pocket cost would be over $2,000 for this drug.
5Patient Review
2/25/2016
Aczone for Acne
Aczone is very effective in halting acne growth. I was really blown away by how well it worked. However, the price tag is pretty hefty at $200-$275 per tube (30 grams). And, once your year of insurance coverage runs out, you're stuck paying that high price unless a generic form becomes available (which thankfully will be in September 2016 when the patent expires).
5Patient Review
3/22/2017
Aczone for Acne
Aczone is the only medication that has worked for me. Not only does it quickly reduce swelling and redness, but blemishes are gone within 1-2 days. I highly recommend this to anyone struggling with breakouts!
5Patient Review
10/12/2015
Aczone for Acne
This was the only treatment that helped my acne.
2.3Patient Review
9/8/2015
Aczone for Acne
1.7Patient Review
8/12/2017
Aczone for Acne
The smell of this stuff was really off-putting, and it actually bleached my towels when I used them to dry my hands. On top of that, it made the skin on my fingers peel off! Overall, terrible experience with nasty side effects.
1Patient Review
4/25/2017
Aczone for Acne
Aczone is an overpriced and ineffective medication, distributed by the greedy pharmaceutical company Allergan. Save your money and buy a better product that won't cost you an arm and a leg. I'm switching back to Finacea, which is just as good on my skin and doesn't break the bank.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about aczone

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does Aczone do for skin?

"This medication is used to treat acne by decreasing the number and severity of acne pimples, and also helping pimples that do develop to heal more quickly."

Answered by AI

How long can you use Aczone?

"The recommended treatment time for ACZONE® gel is 12 weeks (3 months). Your doctor will decide if treatment should continue after this time period."

Answered by AI

Is Aczone gel a retinoid?

"The medication Differin is used to treat acne vulgaris and belongs to the drug class called retinoids. Dapsone is a different medication used to treat bacterial infections and belongs to the drug class called antibacterials. A brand name for dapsone is Aczone."

Answered by AI

Does Aczone work for hormonal acne?

"Aczone can be used to treat both facial and body acne. It is most effective for breakouts that are inflammatory, but it can also help treat non-inflammatory breakouts like blackheads and milia."

Answered by AI

Clinical Trials for Aczone

Image of University of Alabama at Birmingham in Birmingham, United States.

Olfactory Training for HIV

18+
All Sexes
Birmingham, AL
The goal of this study is to examine two types of olfactory interventions (olfactory training vs overnight odor diffuser) in adults with HIV. The two research questions are: 1. Determine if participants find the intervention acceptable and assess feasibility of the study. 2. Determine if the intervention improves olfactory function and cognitive function. Participants will come to our office and be administered the baseline battery of questions including olfactory and cognitive performance tests. Then they will be randomized and sent home with one of the two interventions (below) in which they will engage in it for 8 weeks, after which they come back to our office for the posttest battery of questions including olfactory and cognitive performance test. 1. Olfactory Training at Home -- 4 scents in which they will smell twice a day for 8 weeks. 2. Overnight Diffuser Group -- a single scent diffuser that participants will turn on while they sleep and use for 8 weeks.
Phase < 1
Waitlist Available
University of Alabama at Birmingham
Image of Los Angeles General Medical Center in Los Angeles, United States.

Decision Support Tool for HIV Treatment

18+
All Sexes
Los Angeles, CA
This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients. HIV medicines, known as antiretroviral therapy (ART), can be complex to manage because the right regimen depends on many factors-such as drug resistance, other health conditions, and medication schedules. Many people with HIV are cared for by general clinicians who may not have access to HIV specialists, which can make treatment decisions more challenging. In this study, healthcare providers will use patient cases to compare standard HIV treatment resources with a new clinical decision support tool that gives evidence-based ART recommendations at the point of care. The investigators hypothesize that using the tool will help providers select treatment plans that better match clinical guidelines, make decisions faster, reduce mental effort, and increase overall satisfaction with the prescribing process.
Waitlist Available
Has No Placebo
Los Angeles General Medical CenterHayoun Lee, PhD
Image of University of North Carolina in Chapel Hill, United States.

MGD020 + MGD014 for HIV

18 - 65
All Sexes
Chapel Hill, NC
This research study aims to find out how safe and well tolerated the experimental study drugs are when given to persons with HIV (PWH) taking antiretroviral therapy (ART). The study treatments are MGD014 and MGD020, which are two antibodies developed specifically for HIV, and Vorinostat, an oral medication to help expose HIV in cells to the antibodies. The study will measure the impact of study treatment on non-active HIV in cells, and how long MGD014 and MGD020 stay in the body after they are given. In this study, participants will be randomly assigned to one of three groups. All participants receive MGD014 and MGD020, given sequentially as infusions through an IV for 4 doses. Participants in one group (group A) receive only MGD014 and MGD020. Participants in another group (group B) will stop taking their ART therapy for up to 8 weeks (a temporary treatment interruption (TTI)) while receiving MGD014 and MGD020. Participants in the third group (group C) receive Vorinostat in addition to MGD014 and MGD020. Total time of participation is about 8 months and involves 13 or 18 visits, depending on group assignment.
Phase 1
Recruiting
University of North CarolinaCynthia L. Gay, MD
Have you considered Aczone clinical trials? We made a collection of clinical trials featuring Aczone, we think they might fit your search criteria.Go to Trials
Image of Center on Substance Use and Health in San Francisco, United States.

CHAMPION Intervention for Pre-exposure Prophylaxis Adherence

18 - 40
Male
San Francisco, CA
The goal of this randomized controlled trial is to pilot test new mobile health (mHealth) interventions to improve PrEP adherence among HIV-negative men who have sex with men (MSM) with mild to moderate methamphetamine use disorder (MUD). The CHAMPION intervention combines two mHealth tools-PrEPAPP and CBT4CBT-to address both HIV prevention and MUD treatment needs in this population. The study's specific aims are: * To evaluate the feasibility and acceptability of the CHAMPION intervention based on treatment retention and engagement rates. * To examine the preliminary efficacy the CHAMPION intervention to improve PrEP adherence, as measured by dried blood spot (DBS) tests compared to the waitlist control group.
Waitlist Available
Has No Placebo
Center on Substance Use and HealthGlenn-Milo Santos, PhD, MPH
Have you considered Aczone clinical trials? We made a collection of clinical trials featuring Aczone, we think they might fit your search criteria.Go to Trials
Image of UCSF in San Francisco, United States.

N-803 for HIV

18 - 70
All Sexes
San Francisco, CA
Even though HIV medicine stops the virus from making more copies of itself, the virus remains in the body by hiding inside of immune cells. This hidden virus is referred to as the "latent reservoir." Researchers on this team are studying whether stimulating the immune system can change the nature of the latent reservoir and if this could help people control HIV without the need to take regular HIV medicine. This study is testing a drug called N-803. N-803 is also known as Interleukin-15 or "IL-15", a powerful and long lasting protein that can affect the immune system by stimulating immune cells such as CD8+ T cells and natural killer (NK) cells. CD8+ T cells and NK cells are both crucial for eliminating infected cells. The drug is FDA-approved for the treatment of bladder cancer, but in this study the drug is being used experimentally for HIV.
Phase 2
Waitlist Available
UCSF
Image of Alabama CRS (Site ID: 31788) in Birmingham, United States.

Dasatinib + Quercetin for HIV

18+
All Sexes
Birmingham, AL
This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib and quercetin (D+Q) in improving physical function for people with HIV who are frail or prefrail. The study will involve 80 participants, all aged 50 or older, who have been living with HIV for at least 10 years determined to meet criteria for diagnosis of frail or prefrail and are currently on a stable antiretroviral therapy with viral suppression. Participants will be randomly assigned to one of two groups: one group will receive the D+Q treatment, and the other will receive a placebo. The treatment will be given in six cycles over 12 weeks, with participants taking the medication for two days followed by 12 days without treatment. After the 12-week treatment period, participants will be monitored for another 12 weeks to assess the long-term effects. The study aims to determine if D+Q can improve physical function and other health outcomes in this population. Randomization will be stratified by sex and age to ensure balanced groups.
Phase 2
Waitlist Available
Alabama CRS (Site ID: 31788) (+26 Sites)
Image of Yale University in New Haven, United States.

DynamiCare + Patient Navigation for Stimulant Use Disorder

18+
All Sexes
New Haven, CT
Justice-involved individuals face disproportionately high rates of stimulant use disorder and HIV, along with disrupted access to HIV treatment and prevention services like ART and PrEP. Contingency management (CM) is the most effective intervention for stimulant use, but its use in justice-involved populations has been limited by logistical and structural barriers. DynamiCare is an FDA-approved mobile app that delivers behavioral CM and has shown promise in reducing stimulant use, but its impact on HIV-related outcomes remains unknown. The RESTORE study (Recovery and Engagement for Stimulant Users on Re-entry) will evaluate whether combining DynamiCare with patient navigation (DynamiCare-plus) improves PrEP/ART initiation and reduces stimulant use among individuals recently released from justice settings. The R61 phase will assess feasibility, acceptability, and preliminary effectiveness among 40 participants. If milestones are met, the R33 phase will scale to a randomized controlled trial with 252 participants to assess effectiveness, implementation, and cost. This scalable, mobile approach has the potential to address a critical gap in care for a highly vulnerable population.
Waitlist Available
Has No Placebo
Yale University (+1 Sites)Ank Nijhawan, MD
Have you considered Aczone clinical trials? We made a collection of clinical trials featuring Aczone, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security